Allogene Therapeutics, Inc. — Revenue by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/f09380e0-3009-4647-94e3-36aa53be0341/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $0 | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-017242 |
| FY 2024 | $22.0k | 2024-01-01 – 2024-12-31 | evidence 0001737287-25-000036 |
| FY 2023 | $95.0k | 2023-01-01 – 2023-12-31 | evidence 0001737287-24-000021 |
| FY 2022 | $156.0k | 2022-01-01 – 2022-12-31 | evidence 0001737287-24-000018 |
| FY 2021 | $114.1M | 2021-01-01 – 2021-12-31 | evidence 0001737287-24-000018 |
| FY 2020 | $0 | 2020-01-01 – 2020-12-31 | evidence 0001737287-22-000013 |
| FY 2019 | $0 | 2019-01-01 – 2019-12-31 | evidence 0001737287-22-000013 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Allogene Therapeutics, Inc. — all facts · Net Income · Operating Income